Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages E1854-E1861

  Kanbay, Mehmet ^a,e   Siriopol, Dimitrie ^a,b   Saglam, Mutlu ^a,c   Kurt, Yasemin Gulcan ^a,c   Gok, Mahmut ^a,c   Cetinkaya, Hakki ^a,c   Karaman, Murat ^a,e   Unal, Hilmi Umut ^a,c   Oguz, Yusuf ^a,c   Sari, Sebahattin ^a,c   Eyileten, Tayfun ^a,c   Goldsmith, David ^a,d   Vural, Abdulgaffar ^a,c   Veisa, Gabriel ^a,b   Covic, Adrian ^a,b   Yilmaz, Mahmut Ilker ^a,c  

^a ISTANBUL MEDENIYET UNIVERSITY   (Turkey)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e KOÇ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBROBLAST GROWTH FACTOR 23; MINERAL; PHOSPHATE; SCLEROSTIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR; GENETIC MARKER; SOST PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; ARTICLE; BLOOD FLOW; BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL AND BONE DISORDER; MORTALITY; OBSERVATIONAL METHOD; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SCLEROSTIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SURVIVAL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION; BLOOD; GENETIC MARKER; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; CARDIOVASCULAR DISEASES; CHOLESTEROL; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTORS; GENETIC MARKERS; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASODILATION;

EID: 84907647155     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2042     Document Type: Article

References (40)

1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339-352.
2. Moe SM, Radcliffe JS, White KE, et al. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res. 2011;26:2672-2681.
3. Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int. 2014;85:142-150.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The N Engl J Med. 2004;351:1296-1305.
5. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520-528.
6. Baron R, Rawadi G. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep. 2007;5:73-80.
7. Sabbagh Y, Graciolli FG, O'Brien S, et al. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012;27:1757-1772.
8. de Oliveira RB, Graciolli FG, dos Reis LM, et al. Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant. 2013;28:2510-2517.
9. Cejka D, Marculescu R, Kozakowski N, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab. 2014;99:248-255.
10. Thambiah S, Roplekar R, Manghat P, et al. Circulating sclerostin and dickkopf-1 (dkk1) inpredialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012;90:473-480.
11. Cejka D, Jäger-Lansky A, Kieweg H, et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2012;27:226-230.
12. Cejka D, Herberth J, Branscum AJ, Fardo DW, et al. Sclerostin and dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011;6:877-882.
13. Claes KJ, Viaene L, Heye S, Meijers B, d'Haese P, Evenepoel P. Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab. 2013;98:3221-3228.
14. Brandenburg VM, Kramann R, Koos R, et al. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol. 2013;14:219.
15. Viaene L, Behets GJ, Claes K, et al. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant. 2013;28:3024-3030.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461-470.
18. Solak Y, Yilmaz MI, Saglam M, et al. Mean corpuscular volume is associated with endothelial dysfunction and predicts composite cardiovascular events in patients with chronic kidney disease. Nephrology (Carlton). 2013;18:728-735.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
20. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
21. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.
22. Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab. 2013;98:3873-3883.
23. Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98:4030-4037.
24. Seifert ME, de las Fuentes L, Rothstein M, et al. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol. 2013;38:158-167.
25. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013;24:489-494.
26. Ferreira J, Ferrari GO, Neves KR, et al. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease-role of sclerostin? PLoS One. 2013;8(11):e79721.
27. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (tcf7l2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320-323.
28. Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A. Adipogenesis and Wnt signalling. Trends Endocrinol Metab. 2009;20:16-24.
29. Magoori K, Kang MJ, Ito MR, et al. Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosisin mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein e. J Biol Chem. 2003;278:11331-11336.
30. Kogianni G, Noble BS. The biology of osteocytes. Curr Osteoporos Rep. 2007;5:81-86.
31. Parhami F, Jackson SM, Tintut Y, et al. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res. 1999;14:2067-2078.
32. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945-1953.
33. Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PloS One. 2011;6:e19595.
34. Koos R, Brandenburg V, Mahnken AH, et al. Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis. 2013;22:317-325.
35. Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the wnt signalling pathway (dickkopf-1 (dkk1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013;56:42-47.
36. Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics. 2010;9:2048-2062.
37. Register TC, Hruska KA, Divers J, et al. Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the african american-diabetes heart study. J Clin Endocrinol Metab. 2014;99:315-321.
38. Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int. 2008;73:1024-1030.
39. Taliercio JJ, Schold JD, Simon JF, et al. Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population. Am J Kidney Dis. 2013;62:703-710.
40. Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant. 2010;25:3003-3011.